IGF1 and lung carcinoma: Recent studies have demonstrated the possible potential molecular pathways for SPHK1 and HAS2 in cancer progression, one of which is that SPHK1 induces lung cancer cell migration and paclitaxel resistance by modulating IGF-1-induced EMT [27].